BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the signs and symptoms associated with Fuzeon injection (90mg sc)
using the B2000 needle-free injection device, in HIV-1 positive patients experienced to
Fuzeon treatment, but having difficulty tolerating long-term (>4 weeks) administration of
Fuzeon with the standard needle and syringe. Patients will be randomized to the B2000 device
or the standard needle and syringe for 4 weeks; all patients will use the B2000 device for
the next 4 weeks. The anticipated time on study treatment is <3 months, and the target sample
size is 100-500 individuals.